文献速递其他结缔组织病

A型肉毒毒素治疗系统性硬化症继发雷诺现象的疗效与安全性:一项多中心、随机、双盲、安慰剂对照研究

Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
PubMed 文献 · Arthritis Rheumatol · 2022-12-14

这项多中心、随机、双盲、安慰剂对照III期试验纳入46例BTA组和44例安慰剂组系统性硬化症继发雷诺现象患者,冬季单次双手掌部神经血管束周围注射50单位BTA或安慰剂。主要终点(基线至注射后4周每日雷诺现象发作次数中位数变化)两组相似(BTA组-1次/天 vs 安慰剂组-1次/天,P=0.77),次要终点亦无显著差异;BTA组短暂手部肌肉无力显著更常见(P=0.003)。结论为主要和次要终点均未达到,结果不支持掌部BTA注射治疗SSc-RP的获益。

要点

  • 主要终点每日雷诺现象发作次数中位数变化BTA组-1次/天 vs 安慰剂组-1次/天,P=0.77。
  • 雷诺条件评分、健康评估问卷残疾指数、QuickDASH和Cochin手功能量表变化两组均无显著差异。
  • BTA组短暂手部肌肉无力显著更常见(P=0.003)。

核心结论

  • 主要和次要终点均未达到,结果不支持掌部BTA注射治疗系统性硬化症继发雷诺现象有任何获益。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照、平行组III期试验,纳入系统性硬化症继发雷诺现象患者。
  • 冬季单次双手掌部每个神经血管束周围注射50单位BTA或安慰剂。
  • 意向治疗分析纳入46例BTA组和44例安慰剂组患者。
  • 主要终点为基线(第0天)至注射后4周每日雷诺现象发作次数中位数变化的组间差异,采用Wilcoxon秩和检验比较。

主要发现

  • 注射后4周每日雷诺现象发作次数中位数变化BTA组-1次/天(IQR -1.5, 0)vs 安慰剂组-1次/天(IQR -2.5, 0),P=0.77。
  • 基线至随访第4、12、24周雷诺条件评分、健康评估问卷残疾指数评估的生活质量、QuickDASH和Cochin手功能量表评估的手功能变化两组均无显著差异。
  • BTA组短暂手部肌肉无力显著更常见(P=0.003)。

关键数值与推荐

  • 主要终点:每日雷诺现象发作次数中位数变化BTA组-1次/天(IQR -1.5, 0)vs 安慰剂组-1次/天(IQR -2.5, 0),P=0.77。
  • BTA组短暂手部肌肉无力显著更常见(P=0.003)。

临床怎么用

  • 原文结论未据此给出推荐,仅指出结果不支持掌部BTA注射治疗系统性硬化症继发雷诺现象有任何获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether a single session of botulinum toxin type A (BTA) injections into both hands more effectively decreases the frequency of systemic sclerosis-associated Raynaud's phenomenon (SSc-RP) episodes than placebo. METHODS: This multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III trial in patients with SSc-RP assessed the effect of 50-unit BTA or placebo injections into the palms of both hands around each neurovascular bundle during 1 session in winter. The primary end point was the between-group difference in the median change in the number of RP episodes from baseline (day 0) to 4 weeks postinjection. Values between the groups were compared with the Wilcoxon rank-sum test. RESULTS: The intent-to-treat analysis included 46 BTA-treated patients and 44 placebo recipients. At 4 weeks after assigned treatment injections, the median number of daily RP episodes decreased comparably in the BTA and placebo groups (median change -1 episode/day [interquartile range (IQR) -1.5, 0 episodes/day] and -1 episode/day [IQR -2.5, 0 episodes/day], respectively) (P = 0.77 versus placebo). Moreover, change in Raynaud's Condition Score, quality of life assessed by Health Assessment Questionnaire disability index, and hand function assessed by shortened Disabilities of the Arm, Shoulder, and Hand (QuickDASH) and Cochin Hand Function Scale from baseline to follow-up weeks 4, 12, and 24 did not differ significantly between groups. The BTA group experienced transient hand muscle weakness significantly more frequently (P = 0.003). CONCLUSION: Neither the primary nor secondary end points were reached, and our results do not support any beneficial effect of palmar BTA injections to treat SSc-RP.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Senet P, Maillard H, Diot E, et al. Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Rheumatol. 2022. PMID: 36066501. doi:10.1002/art.42342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。